GB2325225B - Benzofurazan compounds which enhance AMPA receptor activity - Google Patents

Benzofurazan compounds which enhance AMPA receptor activity

Info

Publication number
GB2325225B
GB2325225B GB9809221A GB9809221A GB2325225B GB 2325225 B GB2325225 B GB 2325225B GB 9809221 A GB9809221 A GB 9809221A GB 9809221 A GB9809221 A GB 9809221A GB 2325225 B GB2325225 B GB 2325225B
Authority
GB
United Kingdom
Prior art keywords
compounds
ampa receptor
receptor activity
receptors
ampa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9809221A
Other languages
English (en)
Other versions
GB2325225A (en
GB9809221D0 (enExample
GB2325225A8 (en
Inventor
Gary A Rogers
Christopher M Marrs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortex Pharmaceuticals Inc
Original Assignee
Cortex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharmaceuticals Inc filed Critical Cortex Pharmaceuticals Inc
Publication of GB9809221D0 publication Critical patent/GB9809221D0/en
Publication of GB2325225A publication Critical patent/GB2325225A/en
Publication of GB2325225A8 publication Critical patent/GB2325225A8/en
Application granted granted Critical
Publication of GB2325225B publication Critical patent/GB2325225B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Luminescent Compositions (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
GB9809221A 1997-02-13 1998-02-13 Benzofurazan compounds which enhance AMPA receptor activity Expired - Fee Related GB2325225B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/800,108 US6110935A (en) 1997-02-13 1997-02-13 Benzofurazan compounds for enhancing glutamatergic synaptic responses
PCT/US1998/002713 WO1998035950A1 (en) 1997-02-13 1998-02-13 Benzofurazan compounds which enhance ampa receptor activity

Publications (4)

Publication Number Publication Date
GB9809221D0 GB9809221D0 (enExample) 1998-07-01
GB2325225A GB2325225A (en) 1998-11-18
GB2325225A8 GB2325225A8 (en) 1999-02-17
GB2325225B true GB2325225B (en) 1999-03-03

Family

ID=25177504

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9809221A Expired - Fee Related GB2325225B (en) 1997-02-13 1998-02-13 Benzofurazan compounds which enhance AMPA receptor activity

Country Status (24)

Country Link
US (3) US6110935A (enExample)
EP (2) EP1428534B1 (enExample)
JP (1) JP4446023B2 (enExample)
KR (1) KR100544295B1 (enExample)
CN (1) CN1085206C (enExample)
AT (2) ATE326221T1 (enExample)
AU (1) AU737802C (enExample)
BR (1) BR9807333B1 (enExample)
CA (1) CA2279319C (enExample)
CZ (1) CZ299765B6 (enExample)
DE (2) DE69823803T2 (enExample)
DK (2) DK0960105T3 (enExample)
ES (2) ES2264078T3 (enExample)
GB (1) GB2325225B (enExample)
HU (1) HUP0002303A3 (enExample)
ID (1) ID22342A (enExample)
IL (1) IL131200A (enExample)
NO (1) NO318935B1 (enExample)
NZ (1) NZ336980A (enExample)
PL (1) PL199135B1 (enExample)
PT (2) PT960105E (enExample)
RU (1) RU2189984C2 (enExample)
TR (1) TR199901941T2 (enExample)
WO (1) WO1998035950A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188837B (enExample) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
AU2002366756A1 (en) * 2001-12-20 2003-07-09 Alangudi Sankaranarayanan Use of benzofuroxan derivatives as antiplatelet agents
BRPI0406736A (pt) * 2003-01-13 2005-12-20 Cortex Pharma Inc Método de tratar declìnico cognitivo devido à privação de sono e estresse
JP4829791B2 (ja) * 2003-05-23 2011-12-07 バジリア ファルマスーチカ アーゲー フラザノベンゾイミダゾール
EP1715863B1 (en) * 2004-01-26 2012-05-09 Cortex Pharmaceuticals, Inc. Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
EP2061471A4 (en) * 2006-08-31 2012-02-01 Univ Alberta PROCESS FOR INHIBITING RESTRICTED DEPRESSION WITH POSITIVE ALLOSTER AMPA RECEPTOR MODULATORS
EP2114158B1 (en) * 2007-01-03 2012-08-08 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
CN101616592B (zh) * 2007-01-03 2013-06-05 瑟维尔实验室 用于提高谷氨酸能突触响应的3-取代的-[1,2,3]-苯并三嗪酮化合物
TW200911768A (en) * 2007-05-17 2009-03-16 Cortex Pharma Inc Di-substituted amides for enhancing glutamatergic synaptic responses
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
WO2010087981A2 (en) * 2009-02-02 2010-08-05 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
CA2829006A1 (en) 2011-03-04 2012-09-13 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
CN102633731B (zh) * 2012-03-13 2014-04-30 四川大学华西医院 6-喹喔啉甲酸酰胺化合物、制备方法和应用
KR101421032B1 (ko) * 2012-12-28 2014-07-22 주식회사 레고켐 바이오사이언스 (2-메틸-1-(3-메틸벤질)-1H-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법
CA2915405A1 (en) 2013-06-13 2014-12-18 Veroscience Llc Compositions and methods for treating metabolic disorders
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
WO1994002475A1 (en) * 1992-07-24 1994-02-03 The Regents Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
EP0709384A1 (de) * 1994-10-31 1996-05-01 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
WO1997036907A1 (en) * 1996-04-03 1997-10-09 The Regents Of The University Of California Benzoxazines for enhancing synaptic response

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2499991A1 (fr) * 1981-02-19 1982-08-20 Sandoz Sa Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
US4420485A (en) * 1982-09-29 1983-12-13 Hoechst-Roussel Pharmaceuticals Inc. 1'-[3-(1,2-Benzisoxazol-3-yl) proply]spiro[benzofuran-2(3H),3' or 4'-piperidines or 3'-pyrrolidines]
SU1657189A1 (ru) * 1988-05-23 1991-06-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ коррекции апато-абулических состо ний при шизофрении
SU1587050A1 (ru) * 1988-12-23 1990-08-23 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Производные (7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амина в качестве промежуточных продуктов в синтезе 2-[(7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амино]-5-бром-N-(4-хлорфенил)бензамида, обладающего антигельминтной активностью
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
WO1994002475A1 (en) * 1992-07-24 1994-02-03 The Regents Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
EP0709384A1 (de) * 1994-10-31 1996-05-01 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
WO1997036907A1 (en) * 1996-04-03 1997-10-09 The Regents Of The University Of California Benzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
ATE326221T1 (de) 2006-06-15
EP0960105A1 (en) 1999-12-01
AU6159998A (en) 1998-09-08
GB2325225A (en) 1998-11-18
NO993768L (no) 1999-09-23
NZ336980A (en) 2000-08-25
WO1998035950A1 (en) 1998-08-20
CA2279319A1 (en) 1998-08-20
DK0960105T3 (da) 2004-08-30
DE69834590D1 (de) 2006-06-22
GB9809221D0 (enExample) 1998-07-01
EP1428534A1 (en) 2004-06-16
NO318935B1 (no) 2005-05-30
AU737802B2 (en) 2001-08-30
CA2279319C (en) 2008-08-05
DE69823803D1 (de) 2004-06-17
BR9807333B1 (pt) 2011-10-18
AU737802C (en) 2005-05-12
CZ279599A3 (cs) 2000-01-12
IL131200A0 (en) 2001-01-28
DK1428534T3 (da) 2006-06-12
GB2325225A8 (en) 1999-02-17
CZ299765B6 (cs) 2008-11-19
US6730677B2 (en) 2004-05-04
IL131200A (en) 2005-06-19
KR100544295B1 (ko) 2006-01-23
CN1085206C (zh) 2002-05-22
ID22342A (id) 1999-09-30
HUP0002303A3 (en) 2002-09-30
JP4446023B2 (ja) 2010-04-07
EP1428534B1 (en) 2006-05-17
US6313115B1 (en) 2001-11-06
CN1247534A (zh) 2000-03-15
NO993768D0 (no) 1999-08-04
RU2189984C2 (ru) 2002-09-27
ES2264078T3 (es) 2006-12-16
BR9807333A (pt) 2000-04-18
JP2001512459A (ja) 2001-08-21
DE69823803T2 (de) 2005-04-14
US20020055508A1 (en) 2002-05-09
KR20000071082A (ko) 2000-11-25
PT1428534E (pt) 2006-07-31
TR199901941T2 (xx) 1999-12-21
PL335058A1 (en) 2000-03-27
HUP0002303A2 (hu) 2001-04-28
EP0960105B1 (en) 2004-05-12
ES2221152T3 (es) 2004-12-16
ATE266649T1 (de) 2004-05-15
PL199135B1 (pl) 2008-08-29
DE69834590T2 (de) 2007-04-26
US6110935A (en) 2000-08-29
PT960105E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
GB2325225B (en) Benzofurazan compounds which enhance AMPA receptor activity
NZ331992A (en) Substituted piperidyl or pyrrolyl fused benzoxazinone derivatives and medicaments
DE69625518D1 (de) Wirkstoff zur behandlung neurodegenerativer störungen
DE69435303D1 (de) Er behandlung von krankheiten bei denen eine cytok
PT839134E (pt) Benzoilpiperidinas/pirrolidinas para melhoramento da resposta sinaptica
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
ES2162257T3 (es) N-aminoalquildibenzofurancarboxamidas como ligandos especificos del subtipo de receptor de la dopamina.
DK1054673T3 (da) Benzoxazinforbindelser til forstærkelse af synaptisk reaktion
BR9612074A (pt) Novos 4-(1h-benzimidazol-2-il)(1,4) diazepanos substituidos úteis para o tratamento de doenças alérgicas
PT1067935E (pt) Acilbenzoxazinas para melhorar resposta (s) sinaptica (s)
ATE112557T1 (de) Azetidinderivate, zusammensetzungen und ihre verwendung.
EA200400584A1 (ru) Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов
BR0015402A (pt) Derivados de ácido 15-hidroxieicosatetraenóico de cadeia Èmega modificada e métodos de seu uso para o tratamento de olho seco
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
CA2249654A1 (en) Benzoxazines for enhancing synaptic response
TH28200B (th) การใช้ (สูตร) il -อะโกนิสท์สำหรับรักษาการกลั้นปัสสาวะไม่อยู่

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20020213